LivaNova PLC (NASDAQ:LIVN) Receives $81.38 Consensus Target Price from Analysts

Shares of LivaNova PLC (NASDAQ:LIVN) have earned an average recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $81.3750.

LIVN has been the subject of several research reports. Mizuho increased their target price on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Barclays boosted their price target on LivaNova from $73.00 to $76.00 and gave the stock an “equal weight” rating in a report on Thursday, May 7th. Robert W. Baird lowered their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Zacks Research upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Finally, Freedom Capital upgraded shares of LivaNova to a “hold” rating in a research report on Tuesday, June 30th.

Insider Transactions at LivaNova

In other news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Several institutional investors have recently modified their holdings of the business. GAMMA Investing LLC raised its position in LivaNova by 18.2% during the 2nd quarter. GAMMA Investing LLC now owns 1,838 shares of the company’s stock worth $151,000 after purchasing an additional 283 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of LivaNova by 4.1% in the first quarter. Pacer Advisors Inc. now owns 17,336 shares of the company’s stock valued at $1,102,000 after buying an additional 675 shares during the period. Segall Bryant & Hamill LLC bought a new position in shares of LivaNova during the first quarter worth about $665,000. Janus Henderson Group PLC lifted its stake in shares of LivaNova by 1,978.8% in the first quarter. Janus Henderson Group PLC now owns 471,379 shares of the company’s stock worth $29,961,000 after acquiring an additional 448,703 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in LivaNova by 103.6% in the first quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock valued at $103,000 after acquiring an additional 826 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

LivaNova Stock Up 1.9%

Shares of NASDAQ:LIVN opened at $82.09 on Friday. The company has a fifty day moving average of $78.66 and a 200-day moving average of $69.83. The company has a market capitalization of $4.51 billion, a PE ratio of 42.10 and a beta of 0.86. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. LivaNova has a 52-week low of $41.01 and a 52-week high of $85.27.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.LivaNova’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the business posted $0.88 EPS. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities analysts predict that LivaNova will post 3.73 EPS for the current fiscal year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.